Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin

Schumann, Canan; Chan, Stephanie; Millar, Jess A.; Bortnyak, Yuliya; Carey, Katherine; Fedchyk, Alex; Wong, Leon; Korzun, Tetiana; Moses, Abraham S.; Lorenz, Anna St; Shea, Delany; Taratula, Olena; Khalimonchuk, Oleh; Taratula, Oleh

doi:10.1016/j.nano.2018.03.005

Cited by 26 publications

(15 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To mitigate this effect an enhanced influx into the cancer cells can be achieved with electroporation in the process of electrochemotherapy. 49,50,51 This method increases the cytotoxicity up to 80-fold in cisplatin-sensitive as well as cisplatin-resistant tumour types. 52 Other approach include the synthesis of novel platinum compounds with more lipophilic leaving groups with potential antitumor effect.…”

Section: Clinical Applicationsmentioning

confidence: 99%

Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy

Makovec

2019

Radiology and Oncology

348

246

View full text Add to dashboard Cite

Background Platinum-based anticancer drugs are widely used in the chemotherapy of human neoplasms. The major obstacle for the clinical use of this class of drugs is the development of resistance and toxicity. It is therefore very important to understand the chemical properties, transport and metabolic pathways and mechanism of actions of these compounds. There is a large body of evidence that therapeutic and toxic effects of platinum drugs on cells are not only a consequence of covalent adducts formation between platinum complexes and DNA but also with RNA and many proteins. These processes determine molecular mechanisms that underlie resistance to platinum drugs as well as their toxicity. Increased expression levels of various transporters and increased repair of platinum-DNA adducts are both considered as the most significant processes in the development of drug resistance. Functional genomics has an increasing role in predicting patients’ responses to platinum drugs. Genetic polymorphisms affecting these processes may play an important role and constitute the basis for individualized approach to cancer therapy. Similar processes may also influence therapeutic potential of nonplatinum metal compounds with anticancer activity. Conclusions Cisplatin is the most frequently used platinum based chemotherapeutic agent that is clinically proven to combat different types of cancers and sarcomas.

show abstract

Section: Clinical Applicationsmentioning

confidence: 99%

Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy

Makovec

2019

Radiology and Oncology

348

246

View full text Add to dashboard Cite

show abstract

“…[ 10–14 ] Numerous reports suggest that nanoparticles have the potential to improve conventional therapeutic (e.g., chemotherapy) and imaging (e.g., MRI) modalities for disease detection and treatment. [ 12,15 ] Nanomaterials allow further development of new experimental treatment and imaging strategies, [ 16–19 ] including photothermal therapy (PTT), [ 20,21 ] magnetic hyperthermia, [ 22 ] and photoacoustic imaging. [ 23 ] Nanoparticles are promising vehicles for the delivery of drugs and imaging agents to disease sites.…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, they can extend the circulation time of drugs in the blood, allowing them to reach their therapeutic targets, and to deliver greater amounts of drugs to their target sites more precisely while reducing systemic toxicity via passive targeting or through the use of active targeting moieties. [ 16,17,21,24–29 ] Although the application of nanoparticles for imaging and treatment of endometriosis is a relatively new field, a growing number of reports suggest that nanomedicine has the potential to provide novel therapeutic and diagnostic strategies for this devastating disease ( Table 1 ).…”

Section: Introductionmentioning

confidence: 99%

Nanomedicines for Endometriosis: Lessons Learned from Cancer Research

Moses

Demessie

Taratula

et al. 2021

Small

Self Cite

View full text Add to dashboard Cite

Endometriosis is an incurable gynecological disease characterized by the abnormal growth of endometrium‐like tissue, characteristic of the uterine lining, outside of the uterine cavity. Millions of people with endometriosis suffer from pelvic pain and infertility. This review aims to discuss whether nanomedicines that are promising therapeutic approaches for various diseases have the potential to create a paradigm shift in endometriosis management. For the first time, the available reports and achievements in the field of endometriosis nanomedicine are critically evaluated, and a summary of how nanoparticle‐based systems can improve endometriosis treatment and diagnosis is provided. Parallels between cancer and endometriosis are also drawn to understand whether some fundamental principles of the well‐established cancer nanomedicine field can be adopted for the development of novel nanoparticle‐based strategies for endometriosis. This review provides the state of the art of endometriosis nanomedicine and perspective for researchers aiming to realize and exploit the full potential of nanoparticles for treatment and imaging of the disorder.

show abstract

“…In fact, ovarian cancer cells can disseminate from the primary tumor sites and eventually disseminate within the abdominal cavity via the peritoneal fluid [3]. This dissemination allows the malignant cells to bind to the reproductive organs, the bladder, the sigmoid colon, and the omentum, causing an accumulation of abdominal ascites and variable-size implants on the surface of the peritoneum [4]. Two-thirds of peritoneal carcinoma are of gastrointestinal origin, more than 50% of which are of colorectal origin, 20% of gastric origin, and 20% of pancreatic origin.…”

Section: Introductionmentioning

confidence: 99%

Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties

Baydoun

Moralès

Frochot

et al. 2020

JCM

View full text Add to dashboard Cite

Often discovered at an advanced stage, ovarian cancer progresses to peritoneal carcinoma, which corresponds to the invasion of the serosa by multiple tumor implants. The current treatment is based on the combination of chemotherapy and tumor cytoreduction surgery. Despite the progress and standardization of surgical techniques combined with effective chemotherapy, post-treatment recurrences affect more than 60% of women in remission. Photodynamic therapy (PDT) has been particularly indicated for the treatment of superficial lesions on large surfaces and appears to be a relevant candidate for the treatment of microscopic intraperitoneal lesions and non-visible lesions. However, the impact of this therapy on immune cells remains unclear. Hence, the objective of this study is to validate the efficacy of a new photosensitizer [pyropheophorbide a-polyethylene glycol-folic acid (PS)] on human ovarian cancer cells and to assess the impact of the secretome of PDT-treated cells on human peripheral blood mononuclear cells (PBMC). We show that PS, upon illumination, can induce cell death of different ovarian tumor cells. Furthermore, PDT using this new PS seems to favor activation of the immune response by inducing the secretion of effective cytokines and inhibiting the pro-inflammatory and immunosuppressive ones, as well as releasing extracellular vesicles (EVs) prone to activating immune cells. Finally, we show that PDT can activate CD4+ and CD8+ T cells, resulting in a potential immunostimulating process. The results of this pilot study therefore indicate that PS-PDT treatment may not only be effective in rapidly and directly destroying target tumor cells but also promote the activation of an effective immune response; notably, by EVs. These data thus open up good prospects for the treatment of micrometastases of intraperitoneal ovarian carcinosis which are currently inoperable.

show abstract

Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin

Cited by 26 publications

References 46 publications

Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy

Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy

Nanomedicines for Endometriosis: Lessons Learned from Cancer Research

Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties

Contact Info

Product

Resources

About